COYA

Coya Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1835022Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$8.0M

Net Income FY2025

$(21.0M)

EPS (Basic, as reported)

$-1.27

Net Margin FY2025

-267.1%

ROE FY2025

-49.3%

Total Equity

$43.0M

Shares Out

23M

Business description

Coya Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2021–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 8

Fiscal yearFY2021FY2022⚑FY2023⚑FY2024FY2025

Revenue—0648

General & administrative(2)(5)(8)(9)(11)

Total operating expenses(5)(10)(14)(21)(31)

Operating income(5)(10)(8)(17)(23)

Other income (expense), net00121

Pre-tax income—(12)(7)(16)(21)

Income tax expense—0(1)(1)0

Net income(5)(12)(8)(15)(21)

EPS — basic($1.89)($4.73)($0.79)($0.98)($1.27)

EPS — diluted($1.89)($4.73)($0.79)($0.98)($1.27)

Shares outstanding — basic (M)33101517

Shares outstanding — diluted (M)33101517

⚑ Weighted-average shares changed ×3.33 between FY2022 and FY2023 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.50 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.